Literature DB >> 33971833

Development and validation of a survival nomogram for patients with Siewert type II/III adenocarcinoma of the esophagogastric junction based on real-world data.

Jian Chen1, Yu-Jian Xia1, Tian-Yu Liu2, Yuan-Hui Lai3, Ji-Shang Yu1, Tian-Hao Zhang1, Shiyin Ooi2, Yu-Long He4,5.   

Abstract

BACKGROUND: The clinical staging systems for adenocarcinoma of the esophagogastric junction (AEG) are controversial. We aimed to propose a prognostic nomogram based on real-world data for predicting survival of Siewert type II/III AEG patients after surgery.
METHODS: A total of 396 patients with Siewert type II/III AEG diagnosed and treated at the Center for Gastrointestinal Surgery, the First Affiliated Hospital, Sun Yat-sen University, from June 2009 to June 2017 were enrolled. The original data of 29 variables were exported from the electronic medical records system. The nomogram was established based on multivariate Cox regression coefficients, and its performance was measured using Harrell's concordance index (C-index), receiver operating characteristic (ROC) curve analysis and calibration curve.
RESULTS: A nomogram was constructed based on nine variables. The C-index for overall survival (OS) prediction was 0.76 (95% CI, 0.72 to 0.80) in the training cohort, in the validation-1 cohort was 0.79 (95% CI, 0.72 to 0.86), and 0.73 (95% CI, 0.67 to 0.80) in the validation-2 cohort. Time-dependent ROC curves and calibration curves in all three cohorts showed good prognostic predictive accuracy. We further proved the superiority of the nomogram in predictive accuracy for OS to pathological TNM (pTNM) staging system and other independent prognostic factors. Kaplan-Meier survival curves demonstrated the pTNM stage, grade of differentiation, positive lymph node, log odds of positive lymph node and organ invasion were prognostic factors with good discriminative ability.
CONCLUSION: The established nomogram demonstrated a more precise prognostic prediction for patients with Siewert type II/III AEG.

Entities:  

Keywords:  Adenocarcinoma of the esophagogastric junction; Clinical decision support; Nomogram; Prognosis; Real-world data

Year:  2021        PMID: 33971833     DOI: 10.1186/s12885-021-08249-x

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  23 in total

1.  Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram.

Authors:  Andrea Maurichi; Rosalba Miceli; Hanna Eriksson; Julia Newton-Bishop; Jérémie Nsengimana; May Chan; Andrew J Hayes; Kara Heelan; David Adams; Roberto Patuzzo; Francesco Barretta; Gianfranco Gallino; Catherine Harwood; Daniele Bergamaschi; Dorothy Bennett; Konstantinos Lasithiotakis; Paola Ghiorzo; Bruna Dalmasso; Ausilia Manganoni; Francesca Consoli; Ilaria Mattavelli; Consuelo Barbieri; Andrea Leva; Umberto Cortinovis; Vittoria Espeli; Cristina Mangas; Pietro Quaglino; Simone Ribero; Paolo Broganelli; Giovanni Pellacani; Caterina Longo; Corrado Del Forno; Lorenzo Borgognoni; Serena Sestini; Nicola Pimpinelli; Sara Fortunato; Alessandra Chiarugi; Paolo Nardini; Elena Morittu; Antonio Florita; Mara Cossa; Barbara Valeri; Massimo Milione; Giancarlo Pruneri; Odysseas Zoras; Andrea Anichini; Roberta Mortarini; Mario Santinami
Journal:  J Clin Oncol       Date:  2020-03-13       Impact factor: 44.544

2.  Classification of adenocarcinoma of the oesophagogastric junction.

Authors:  J R Siewert; H J Stein
Journal:  Br J Surg       Date:  1998-11       Impact factor: 6.939

Review 3.  Cancer of the gastroesophageal junction: a diagnosis, classification, and management review.

Authors:  Mickael Chevallay; Elfriede Bollschweiler; Servarayan M Chandramohan; Thomas Schmidt; Oliver Koch; Giovanni Demanzoni; Stefan Mönig; William Allum
Journal:  Ann N Y Acad Sci       Date:  2018-08-23       Impact factor: 5.691

4.  Cancer of the esophagus and esophagogastric junction-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Authors:  Thomas W Rice; Donna M Gress; Deepa T Patil; Wayne L Hofstetter; David P Kelsen; Eugene H Blackstone
Journal:  CA Cancer J Clin       Date:  2017-05-26       Impact factor: 508.702

5.  X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.

Authors:  Robert L Camp; Marisa Dolled-Filhart; David L Rimm
Journal:  Clin Cancer Res       Date:  2004-11-01       Impact factor: 12.531

6.  Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer.

Authors:  Bernard H Bochner; Michael W Kattan; Kinjal C Vora
Journal:  J Clin Oncol       Date:  2006-07-24       Impact factor: 44.544

7.  Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy.

Authors:  Yizhou Wang; Jun Li; Yong Xia; Renyan Gong; Kui Wang; Zhenlin Yan; Xuying Wan; Guanghua Liu; Dong Wu; Lehua Shi; Wanyee Lau; Mengchao Wu; Feng Shen
Journal:  J Clin Oncol       Date:  2013-01-28       Impact factor: 44.544

8.  Proposal of a Nomogram for Predicting Survival in Patients with Siewert Type II Adenocarcinoma of the Esophagogastric Junction After Preoperative Radiation.

Authors:  Feng Liu; Rui Zhou; Funeng Jiang; Guolong Liu; Kangbao Li; Guodong Zhu
Journal:  Ann Surg Oncol       Date:  2019-02-25       Impact factor: 5.344

9.  Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making.

Authors:  Si-Ye Chen; Yong Yang; Shu-Nan Qi; Ying Wang; Chen Hu; Xia He; Li-Ling Zhang; Gang Wu; Bao-Lin Qu; Li-Ting Qian; Xiao-Rong Hou; Fu-Quan Zhang; Xue-Ying Qiao; Hua Wang; Gao-Feng Li; Yu-Jing Zhang; Yuan Zhu; Jian-Zhong Cao; Sheng-Min Lan; Jun-Xin Wu; Tao Wu; Su-Yu Zhu; Mei Shi; Li-Ming Xu; Zhi-Yong Yuan; Joachim Yahalom; Richard Tsang; Yu-Qin Song; Jun Zhu; Hang Su; Ye-Xiong Li
Journal:  Leukemia       Date:  2020-03-09       Impact factor: 11.528

View more
  2 in total

1.  Nomograms for Predicting Disease-Free Survival in Patients With Siewert Type II/III Adenocarcinoma of the Esophagogastric Junction Receiving Neoadjuvant Therapy and Radical Surgery.

Authors:  Zhenjiang Guo; Honghai Guo; Yuan Tian; Ze Zhang; Qun Zhao
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

2.  Model established based on blood markers predicts overall survival in patients after radical resection of types II and III adenocarcinoma of the esophagogastric junction.

Authors:  Zhi-Jian Wei; Ya-Ting Qiao; Bai-Chuan Zhou; Abigail N Rankine; Li-Xiang Zhang; Ye-Zhou Su; A-Man Xu; Wen-Xiu Han; Pan-Quan Luo
Journal:  World J Gastrointest Surg       Date:  2022-08-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.